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After a very long and windy road, in December of 2005
the FDA approved CTLA4Ig for the treatment of rheu-
matoid arthritis. Orencia is the first-in-class antago-
nist of CD28 costimulation. In this perspective, we dis-
cuss the science that led to CTLA4Ig development and
the clinical challenges in bringing the drug from the
bench to the bedside.
Introduction
T cell costimulation is among the most important con-
cepts to emerge in basic immunology in the past 30
years. It proposes that an antigen-presenting cell (APC)
must provide two independent signals for full T cell acti-
vation. Signal one is T cell receptor (TCR) stimulation,
provided by antigen (Ag) bound to a major histocompat-
ibility complex molecule (Ag-MHC). Signal two is pro-
vided by a ligand for a T cell-expressed costimulatory
receptor (Lafferty et al., 1983; Lafferty and Woolnough,
1977). Together, both signals lead to optimal cytokine
production, proliferation, effector function, and survival
(June et al., 1994). In contrast, costimulation alone in the
absence of cognate antigen has no effect on the T cell
(June et al., 1994), while provision of signal one (TCR)
without signal two (costimulation) leads to active induc-
tion of T cell unresponsiveness or anergy (Jenkins and
Schwartz, 1987). This paradigm has two important impli-
cations. First, as only ‘‘professional’’ APCs can provide
costimulation, interactions of T cells with self-antigen-
bearing stromal tissues do not generally induce activa-
tion, providing a mechanism for self tolerance even in
the presence of an autoreactive T cell repertoire. Sec-
ond, the concept of costimulation identified new impor-
tant targets for drug development because tolerance
might be achieved by blocking costimulation, even if
the relevant antigens were numerous (transplantation)
or not known (many autoimmune diseases). Thus, tar-
geting costimulatory receptors became the mantra of
the immune tolerance community.
Over the past two decades, a number of molecules
have been implicated as costimulatory receptors or li-
gands for naive T cells (Greenwald et al., 2005; Quezada
et al., 2004). Although interactions such as CD154 with
*Correspondence: jbluest@immunetolerance.orgits ligand, CD40, have profound effects on immune re-
sponses, the monovalent homodimer CD28, which inter-
acts with CD80 (B7-1) and CD86 (B7-2), remains the
most prominent costimulatory receptor for naive T cells
by providing both a qualitatively distinct second signal
and amplifying the transcriptional effects of TCR trigger-
ing(Lenschow et al., 1996; Salomon and Bluestone,
2001).
Here we summarize the studies of the CD28-costimu-
latory antagonist CTLA4Ig, the first of its class brought
to market, beginning with its topsy-turvy roller coaster
ride through preclinical and clinical development and
culminating with drug approval. We also highlight the
critical basic and clinical observations that have syner-
gized to advance the field and propose future avenues
of research that may further exploit this new class of im-
munoregulatory drugs.
CTLA4Ig as a Potent Inhibitor of CD28-Mediated
T Cell Costimulation
B7-1 (CD80) was the first ligand for CD28 identified,
leading to the use of anti-B7-1 antibodies to block co-
stimulation (Gimmi et al., 1991). However, in several sys-
tems the antibody was ineffective, which we now know
to be due to the presence of a second CD28 ligand,
B7-2 (CD86) (Freeman et al., 1993; Lenschow et al.,
1994). To circumvent this problem, Linsley and co-
workers developed a soluble CD28 fusion protein (Peach
et al., 1994), CD28Ig, with the expectation that it would
block CD28 interactions with both CD80 and CD86.
However, this molecule was ineffective, mainly because
of the low affinity of CD28 for its ligands. Recent struc-
tural analysis has confirmed that the weak monomeric
interactions that exist between CD28 and its ligands re-
sult in poor binding in the absence of a high degree of
multivalency such as that present in the immunologic
synapse during T cell-APC interactions (Jansson et al.,
2005; van der Merwe and Davis, 2003).
At about the same time, Tullia Lindsten and Craig
Thompson showed that a newly discovered protein,
CTLA-4 (Brunet et al., 1987), shared many attributes of
CD28, including a six amino acid sequence (MYPPPY)
that was critical for binding to CD80 and CD86 (Lindsten
et al., 1993). Because CTLA-4 had a higher affinity for
CD80 and CD86 than CD28, the soluble fusion protein
CTLA4Ig became the therapy of choice for blocking
CD28-B7 interactions (Figure 1). CTLA4Ig binds effec-
tively to both CD80 and CD86, although a number of
biophysical and structural studies suggest that CD86
preferentially engages CD28 at the synapse, in contrast
to CD80, which ligates CTLA-4 more effectively than
CD28 (Linsley et al., 1991). In fact, CD80 completely
dominates interactions with CTLA-4, forming linear ar-
rays of receptor-ligand pairs.
Despite its homology to CD28, we and others ob-
served that CTLA-4 is in fact a negative regulator of
CD28-mediated T cell costimulation (Krummel and Alli-
son, 1995; Walunas et al., 1994). Importantly, resting
T cells and APCs primarily express CD28 and CD86, re-
spectively, while activation induces CTLA-4 and CD86
(Jansson et al., 2005; van der Merwe and Davis, 2003).
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234Figure 1. Multiple Effects of CTLA4Ig on Immune Function
CTLA4Ig functions to block the interaction of CD28-B7 during activation of naive and activated helper or cytotoxic T cells (2). The CD28 blockade
results in increased cell death, anergy induction, and blockade of cell differentiation. CTLA4Ig also has another potentially immunosuppressive
effect by interacting with B7 on dendritic cells inducing IDO, which indirectly blocks naive cell activation (1). Finally, CTLA4Ig can potentially have
an immune augmenting effect by blocking the interaction of CTLA-4 with the same B7 ligands on effector cell function (3) or blockade of CD28-B7
interactions on regulatory T cell function (4), which results in enhanced pathogenic T cell activity.Thus, differences in binding avidity of CD28 and CTLA-4
for CD80 and CD86 are critical to understanding the
temporal nature of the immune response, suggesting a
model in which positive signals delivered via CD28:
CD86 dominate initially, while negative signals resulting
from CTLA-4:CD80 ligation serve a counterregulatory
function to terminate T cell responses. Thus, CTLA4Ig,
through its binding to CD80 and CD86, inhibits both co-
stimulation through CD28 as well as negative signaling
via CTLA-4, potentially leading to diverse outcomes de-
pending on the stage of T cell activation.
The development of this effective CD28 antagonist
prompted studies testing its efficacy in vivo. In several
different transplant settings, we and others showed
that short-term CTLA4Ig therapy led to long-term tissue
and organ graft survival, suppression of alloantibody re-
sponses, and, most importantly, induction of tolerance
(Larsen et al., 1996; Lenschow et al., 1992; Lin et al.,
1993). Similar observations in animal models of autoim-
munity suggested that CD28 blockade not only func-
tioned at the initiation of an immune response but could
also ameliorate ongoing immunity (Salomon and Blue-
stone, 2001). Most importantly, in a substantial percent-
age of these studies, CTLA4Ig therapy could be stopped
after a short time, and its effects remained long lived.
Over the last 15 years, the mechanistic basis for
CTLA4Ig function in vivo has become increasingly clear.
First and foremost, CTLA4Ig blocks the engagement of
CD28 with its ligands CD80 and CD86, inhibiting the
early phases of T cell activation, including progression
into cell cycle, effector differentiation, and cell survival
(Salomon and Bluestone, 2001). However, the original
work showing that blockade of T cell costimulation
in vitro results in T cell anergy has not been borne out
in vivo. Individual T cells isolated from treated animalsare able to function ex vivo (Szot et al., 2000). Rather,
we showed that a major effect of costimulation blockade
in vivo is to promote passive (growth factor withdrawal)
cell death and limit the clonal expansion of antigen-reac-
tive T cells (Lakkis et al., 1997; Li et al., 1999; Wells et al.,
1999) and that tolerance induction is critically depen-
dent on this proapoptotic activity.
In addition to these major functions, other in vivo ef-
fects of CTLA4Ig have been described. CTLA4Ig func-
tions in allogeneic islet transplant tolerance by trigger-
ing APC production of indoleamine 2, 3-dioxygenase
(IDO), an intracellular enzyme that breaks down trypto-
phan and suppresses T cell activation (Grohmann
et al., 2002). These data provide an interesting link with
fetal-maternal tolerance, which is also IDO dependent
(Mellor and Munn, 2004) and suggests multiple ways in
which immune regulation following CTLA4Ig treatment
may occur. Moreover, under certain circumstances,
CTLA4Ig can augment immunity. This may occur for
two reasons. First, CTLA4Ig treatment can block ligation
of the negative regulator, CTLA-4, resulting in enhanced
T cell activation (Salomon and Bluestone, 2001). More
importantly, CTLA4Ig treatment has direct effects on
regulatory T cells (Tregs), which are critically important
in the control of autoimmunity and many settings of
transplant tolerance (Salomon et al., 2000). The develop-
ment and peripheral survival of Tregs is CD28 depen-
dent; thus, CTLA4Ig treatment results in a precipitous
reduction of Tregs and in some cases exacerbation of
autoimmunity (Tang et al., 2003). It is unclear whether
these potential adverse effects of CTLA4Ig therapy will
be a critical issue in the human setting. It is likely to de-
pend on location, timing, and the relevant importance
of CTLA-4-expressing activated T cells and Tregs in
controlling immunity in the different diseases. In this
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235context, it is interesting to note that anti-CD86 monoclo-
nal antibody therapy is quite efficacious in several
models due to its dramatic effects on CD28 costimula-
tion with limited affects on CTLA-4 engagement or
Treg survival (Bour-Jordan et al., 2005; Haanstra et al.,
2003; Kirk et al., 2001).
Moving the Drug to the Clinic
The studies of CTLA4Ig in rodent models cited above
were extremely encouraging; however, the pipeline is lit-
tered with drugs that ameliorate mouse diseases but
later fall victim to the rigors of clinical testing. What sep-
arates CTLA4Ig from other promising efforts to modu-
late T cell activation is that this agent, known by the
name abatacept (Orencia, Bristol-Myers Squibb, New
York, New York), is now an approved drug for the treat-
ment of rheumatoid arthritis (http://www.fda.gov/cder/
foi/appletter/2005/125118rev2.pdf).
Reaching this point was not easy—the development
path had many twists and turns as Bristol-Myers Squibb
was challenged legally, clinically, and in drug manufac-
turing. Initial studies focused in the transplant arena us-
ing nonhuman primates. Compared to the results from
murine studies, CTLA4Ig was far less efficacious in this
setting (Kirk et al., 1997; Levisetti et al., 1997). The
drug was not able to block graft rejection alone unless
used continuously. The drug appeared to affect alloanti-
body responses better than T cell-mediated allograft re-
jection. This finding was consistent with mouse studies
showing a profound effect of CTLA4Ig on Th2 immunity;
however, with few exceptions, treatment with CTLA4Ig
failed to induce tolerance in the nonhuman primate
models or to produce long-term graft survival. Mean-
while, another company, Biogen, Inc., (now Biogen
Idec, Cambridge, Massachusetts) was racing forward
to develop a monoclonal antibody to CD40L (CD154),
a potent costimulatory blocker in preclinical animal
models. In studies in nonhuman primates using the
combination of CTLA4Ig and anti-CD40L, blockade of
the CD40L pathway seemed to provide greater
suppression of immune responses (Kirk et al., 1997,
1999).
It appeared initially that Bristol-Myers Squibb would
not continue with the development of CTLA4Ig. How-
ever, several events changed the landscape. First, in
phase II clinical trials, anti-CD40L treatment was associ-
ated with unanticipated side effects (Sidiropoulos and
Boumpas, 2004). A few patients treated with the drug
experienced thromboembolic events most likely due to
reactivity of the monoclonal antibody with CD40L ex-
pressed on the surface of activated platelets. Second,
Bristol-Myers Squibb received encouraging news from
a phase I open-label dose-escalation study of CTLA4Ig
therapy in patients with psoriasis vulgaris (Abrams
et al., 1999), a T cell-dependent skin disorder character-
ized by abnormal keratinocyte proliferation and differen-
tiation, and an inflammatory infiltrate of T cells and APCs
at the dermal-epidermal junction. Nearly half of the pa-
tients in this study achieved 50% or more improvement
in clinical disease activity, with greater response rates in
the cohorts receiving the highest doses. Pre- and post-
treatment skin biopsies showed that this treatment ef-
fect was accompanied by normalization of keratinocyte
proliferation and maturation, a reduction in the numbers
of infiltrating T cells, and diminished expression of CD40and HLA-DR antigens by keratinocytes and of CD80,
CD86, and MHC class II antigens by dendritic cells
(Abrams et al., 2000).
Importantly as well, CTLA4Ig therapy was proving to
have an acceptable toxicity profile. It did not appear to
decrease serum Ig concentrations (Abrams et al.,
2000). Flow cytometry for multiple B and T cell markers
revealed no major alterations in subsets of peripheral
blood lymphocytes. Because animal studies had shown
that treatment with CTLA4Ig abrogated humoral im-
mune responses to T cell-dependent antigens, the pa-
tients with psoriasis in the phase I trial were immunized
with two neoantigens—KLH-Immune Activator and bac-
teriophage VX174. Suppression of antibody titers was
observed for at least some of the patients in each dosing
cohort after primary and secondary immunization with
VX174, as well as secondary immunization with KLH.
However, by the fourth immunization, most patients de-
veloped an immune response to bacteriophage VX174
and KLH equivalent to that of untreated individuals, indi-
cating that CTLA4Ig therapy did not induce permanent
tolerance to these antigens.
There was also progress on the transplant front. A
number of groups undertook efforts to develop higher-
affinity forms of CTLA4Ig that could bind both ligands ef-
fectively. Peach and colleagues observed that two
amino acid mutations in the extracellular domain cre-
ated a molecule, termed LEA29Y, that bound CD80 2-
fold better than CTLA4Ig but, more importantly, bound
CD86 4-fold better. Some have suggested that the mu-
tant form has ten times the binding avidity for CD80
and CD86 compared with CTLA4Ig. LEA29Y showed
significantly greater efficacy in the transplant setting in
nonhuman primates (Larsen et al., 2005), which im-
proved yet further when drug treatment was combined
with other immune modulators (Larsen et al., 2005).
Most importantly, there were relatively few serious ad-
verse effects in these studies.
CTLA4Ig (abatacept) and LEA29Y (belatacept) have
been investigated more recently in human clinical trials
to prevent transplant rejection and treat rheumatoid ar-
thritis. The work in rheumatoid arthritis led to the ap-
proval of abatacept by the US Food and Drug Adminis-
tration on December 30, 2005, for this indication. The
pathway toward approval of abatacept had accelerated
rapidly after a phase II, randomized, double-blind, pla-
cebo-controlled, dose-finding study showed that both
abatacept and belatacept therapy had potential clinical
efficacy in patients with refractory rheumatoid arthritis
(Moreland et al., 2002). Several large, multicenter, ran-
domized, controlled trials were subsequently performed
substantiating the clinical efficacy and safety of abata-
cept for the treatment of rheumatoid arthritis. Response
rates were on par with those found using agents block-
ing tumor necrosis factor-a (TNF) (e.g., etanercept, in-
fliximab, adalimumab), which arguably represent the
most important advance in the treatment of rheumatoid
arthritis over the past decade. Moreover, abatacept
therapy was shown to significantly inhibit radiographic
progression of disease, a surrogate measure of joint
damage. The safety data from these trials continue to re-
veal a favorable profile, although patients receiving
a combination of abatacept and another biologic (e.g.,
TNF blocker) had a higher incidence of serious bacterial
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236infections compared with those receiving nonbiologic
agents or only a single biologic agent.
These results are intriguing because they represent
the first clinical success of a biologic therapy for rheu-
matoid arthritis aimed specifically at inhibiting (or de-
pleting) T cells. Prior T cell-depleting therapies such as
anti-CD4, anti-CD5, and anti-CD52 produced disap-
pointing results in phase I and II trials, suggesting that
wholesale depletion of T cells or major T cell subsets
is not the answer for treating this disease. While cyclo-
sporine, an inhibitor of T cell activation, has been shown
to be effective for the treatment of rheumatoid arthritis, it
may affect other cell types and pathogenic pathways.
Whether or not other therapies for rheumatoid arthritis,
such as methotrexate, ameliorate disease by inhibiting
T cells is uncertain. The clinical efficacy of abatacept
therapy in this setting may therefore provide new clues
to the mechanisms of disease. Unknown still is how
CTLA4Ig therapy reduces joint inflammation and dam-
age in RA. Mechanisms may include blockade of
CD28-mediated T cell activation, induction of IDO, or
even depletion of CD80- and CD86-expressing dendritic
cells via antibody- or complement-dependent cytotox-
icity triggered by the Fc portion of the molecule. Unfor-
tunately, clinical trials with an Fc receptor nonbinding
form of CTLA4Ig (Repligen Corporation) have been
halted due to intellectual property issues. Nevertheless,
these questions provide a context for future mechanistic
studies that may illuminate the mechanisms by which
CTLA4Ig functions to hold persistent inflammatory and
other injurious responses in check.
Finally, there continues to be progress in the clinical
development of belatacept. In a recent phase II trial, all
renal-transplant recipient patients received peritrans-
plant therapy with anti-CD25 (basiliximab), the immuno-
suppressant mycophenolate mofetil, and corticoste-
roids and then were randomly assigned to receive
either of two dosing regiments of belatacept or the cal-
cineurin-inhibiting drug cyclosporine (Vincenti et al.,
2005). The incidence of acute rejection was similar
among the three treatment groups. However, at 12
months, kidney function was significantly better in both
of the belatacept treatment groups compared with the
cyclosporine-treated patients. Chronic allograft ne-
phropathy was also less common in the two groups re-
ceiving belatacept than in the group treated with cyclo-
sporine. These results suggest that this calcineurin
inhibitor-sparing regimen may prevent acute rejection
as well as current therapies and do so with fewer long-
term renal complications.
What Does the Future Hold?
Most importantly, the success of CTLA4Ig drug shows
how breakthroughs in basic immunology are being
translated into new therapies in the clinic, and raises
a number of questions. Will the new agents affecting
costimulatory pathways replace conventional immuno-
suppressive agents? There is no doubt that costimula-
tion blockade has moved from its days as a tool for basic
laboratory investigation to a proven therapy for patients
with immune-mediated diseases. Opportunities for
further advancement seem at hand. The success of aba-
tacept for the treatment of rheumatoid arthritis has cat-
alyzed its investigation as a possible therapy for sys-
temic lupus erythematosus. Other diseases with anestablished therapeutic need and for which T cells have
been strongly implicated in pathogenesis are also likely
to receive attention. New forms of CD28-B7 blockade as
well as other costimulatory inhibitors, such as anti-CD40
and CD154 antagonists (Adams et al., 2005), are on the
horizon and will hopefully avoid toxicities observed
with earlier drug candidates. In addition, the discovery
of new costimulatory pathways will almost certainly
yield more therapeutic targets for clinical testing.
Meanwhile, several important areas will require further
study in patients subject to costimulatory blockade.
First, will chronic costimulatory blockade have long-
term consequences? When costimulatory blockade is
used in combination with other immunomodulatory ther-
apies, will it significantly increase the risk for bacterial or
opportunistic infections, reactivate latent infections
such as herpes zoster or tuberculosis, or reduce the
efficacy of preventative vaccines? Second, CTLA4Ig
therapy may deplete Tregs. Clinical studies are needed
to determine the half-lives of Tregs in vivo to potentially
adjust the dose of CTLA4Ig to block immune activation
while preserving Treg survival (Boden et al., 2003). In
this regard, cancer patients who have been treated
with anti-CTLA-4 to enhance tumor immunity often
develop autoimmune syndromes (Phan et al., 2003). Fi-
nally, there is increasing evidence that CD28 is less crit-
ical for facilitating chronic immune responses (Kemball
et al., 2006). Animal studies have clearly shown that
CD28-B7 interactions are more important for stimulating
naive T cells as opposed to activated effector or memory
T cells. If so, how is abatacept suppressing inflamma-
tion in rheumatoid arthritis? Based on current dogma,
the drug should not be effective if the disease is driven
primarily by memory T cells, which comprise the major-
ity of T cells in the synovial membrane of patients with
rheumatoid arthritis.
We believe two approaches are needed to deal with
these challenges. First, we suggest a rapid movement
toward the testing of combination therapies. Based on
animal studies in a variety of models, the use of CTLA4Ig
combined with another costimulation antagonist or an
immunosuppressive drug will be more effective than
CD28 blockade alone. For example, perhaps simulta-
neous targeting of CD40, ICOS, LFA-1, or other cell ad-
hesion or costimulatory pathways will induce a more
robust immunomodulatory effect. Of course, this more
intensive approach will require the appropriate safety
precautions to minimize risks for toxicity, especially in-
fections. Second, drug withdrawal studies are a critical
next step. A relatively short course of tolerance-inducing
therapy may avoid many of the toxicities associated with
chronic immunosuppressive therapy, such as infection
and cancer. As a community, we must press for contin-
ued development of agents, such as CTLA4Ig, that can
potentially induce immune tolerance in humans and pro-
vide a deeper understanding of the mechanisms that
underlie its nature.
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